A BILL 
To amend the Public Health Service Act to authorize the 
Secretary to make grants and enter into cooperative 
agreements with entities to expand and support activities 
with respect to the prevention and treatment of a covered 
condition, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘COVID–19 Prevention 
4
and Awareness Act of 2021’’. 
5
17:53 Jan 29, 2021
H173
2 
•HR 173 IH
SEC. 2. COVID–19 PREVENTION AND AWARENESS GRANTS. 
1
Subpart I of part D of title III of the Public Health 
2
Service Act (42 U.S.C. 254b et seq.) is amended by adding 
3
at the end the following: 
4
‘‘SEC. 330N. PROGRAM TO PREVENT AND TREAT COVERED 
5
CONDITIONS. 
6
‘‘(a) IN GENERAL.—The Secretary, acting through 
7
the Director of the Centers for Disease Control and Pre-
8
vention, may award grants and enter into cooperative 
9
agreements with covered entities to expand and support 
10
activities with respect to the prevention and treatment of 
11
covered conditions, including— 
12
‘‘(1) conducting screenings, surveillance, and di-
13
agnostic testing for covered conditions; 
14
‘‘(2) providing guidance to individuals on such 
15
prevention and treatment activities; and 
16
‘‘(3) providing guidance on vaccinations rec-
17
ommended by the Advisory Committee on Immuniza-
18
tion Practices established by the Secretary. 
19
‘‘(b) APPLICATION.—An entity seeking a grant under 
20
this section shall submit an application to the Secretary 
21
at such time, in such manner, and accompanied by such 
22
information as the Secretary may require. 
23
‘‘(c) PRIORITY.—In awarding grants or entering into 
24
cooperative agreements under this section, the Secretary 
25
shall give priority to— 
26
17:53 Jan 29, 2021
H173
3 
•HR 173 IH
‘‘(1) federally qualified health centers (as de-
1
fined in section 330A); 
2
‘‘(2) community-based organizations; and 
3
‘‘(3) entities that have an agreement with a fed-
4
erally-qualified health center. 
5
‘‘(d) REPORTS.— 
6
‘‘(1) REPORT TO SECRETARY.—An entity that 
7
receives a grant or enters into a cooperative agree-
8
ment under this section shall submit to the Sec-
9
retary a report that includes— 
10
‘‘(A) a description of each activity carried 
11
out— 
12
‘‘(i) pursuant to the cooperative 
13
agreement; or 
14
‘‘(ii) with amounts received through 
15
the grant; and 
16
‘‘(B) an evaluation of the effectiveness of 
17
each such activity. 
18
‘‘(2) REPORT TO CONGRESS.—Not later than 3 
19
years after the date of the enactment of this section, 
20
the Secretary shall submit to Congress a report on 
21
the effectiveness of the grants and cooperative agree-
22
ments entered into under this section. 
23
‘‘(e) SUPPLEMENT NOT SUPPLANT.—An entity re-
24
ceiving a grant under this section shall use grant amounts 
25
17:53 Jan 29, 2021
H173
4 
•HR 173 IH
to supplement, not supplant, any other Federal, State, and 
1
local funds that would otherwise be expended by such enti-
2
ty to carry out the activities described in this section. 
3
‘‘(f) DEFINITIONS.—In this section: 
4
‘‘(1) COVERED CONDITION.—The term ‘covered 
5
condition’ means a disease or condition that has 
6
been identified by the Centers for Disease Control 
7
and Prevention to increase, or likely increase, the 
8
risk of mortality from COVID–19 or to increase, or 
9
likely increase, the risk of severe illness from 
10
COVID–19, including the following: 
11
‘‘(A) Asthma. 
12
‘‘(B) Cancer. 
13
‘‘(C) Cerebrovascular disease. 
14
‘‘(D) Chronic kidney disease. 
15
‘‘(E) Chronic obstructive pulmonary dis-
16
ease. 
17
‘‘(F) Cystic fibrosis. 
18
‘‘(G) Hypertension or high blood pressure. 
19
‘‘(H) Liver disease. 
20
‘‘(I) Neurologic conditions, including de-
21
mentia. 
22
‘‘(J) Obesity. 
23
‘‘(K) Pregnancy. 
24
‘‘(L) Pulmonary fibrosis. 
25
17:53 Jan 29, 2021
H173
5 
•HR 173 IH
‘‘(M) Serious heart conditions, including 
1
heart failure, coronary artery disease, and car-
2
diomyopathy. 
3
‘‘(N) Sickle cell disease. 
4
‘‘(O) Pulmonary conditions resulting from 
5
tobacco use. 
6
‘‘(P) Thalassemia. 
7
‘‘(Q) Tobacco use. 
8
‘‘(R) Type 1 and 2 diabetes mellitus. 
9
‘‘(S) Weakened immune system, including 
10
from— 
11
‘‘(i) a solid organ transplant; 
12
‘‘(ii) a blood or bone marrow trans-
13
plant; 
14
‘‘(iii) the human immunodeficiency 
15
virus; and 
16
‘‘(iv) the use of a corticosteroid or 
17
other immune weakening medicine. 
18
‘‘(2) COVERED ENTITY.—The term ‘covered en-
19
tity’ includes the following: 
20
‘‘(A) Federally qualified health center (as 
21
defined in section 330A). 
22
‘‘(B) Entity that has an agreement with a 
23
federally qualified health center. 
24
‘‘(C) Community-based organization. 
25
17:53 Jan 29, 2021
H173
6 
•HR 173 IH
‘‘(D) Faith-based organization. 
1
‘‘(E) Nonprofit organization. 
2
‘‘(g) AUTHORIZATION
OF
APPROPRIATIONS.—To 
3
carry out this section, there is authorized to be appro-
4
priated $2,000,000,000 for the period of fiscal years 2021 
5
through 2022, to remain available until expended. 
6
‘‘SEC. 330O. GRANT PROGRAM TO INCREASE AWARENESS 
7
OF THE RELATIONSHIP BETWEEN COVERED 
8
CONDITIONS AND COVID–19. 
9
‘‘(a) IN GENERAL.—The Secretary, acting through 
10
the Director of the Centers for Disease Control and Pre-
11
vention, may award grants to entities to carry out a cam-
12
paign to increase awareness of the relationship between— 
13
‘‘(1) covered conditions; and 
14
‘‘(2) the increased risk of developing a severe 
15
illness or mortality from COVID–19. 
16
‘‘(b) APPLICATION.—An entity seeking a grant under 
17
this section shall submit an application to the Secretary 
18
at such time, in such manner, and accompanied by such 
19
information as the Secretary may require, including a de-
20
scription of how the entity intends to carry out the activi-
21
ties specified in subsection (c). 
22
‘‘(c) CAMPAIGN ACTIVITIES.—In carrying out the 
23
campaign under subsection (a), an entity shall— 
24
17:53 Jan 29, 2021
H173
7 
•HR 173 IH
‘‘(1) develop and disseminate informational ma-
1
terial— 
2
‘‘(A) that is culturally and linguistically 
3
appropriate; 
4
‘‘(B) targeted toward communities and 
5
populations that are at a high risk of— 
6
‘‘(i) developing a covered condition; 
7
and 
8
‘‘(ii) contracting COVID–19; 
9
‘‘(C) that increases awareness of the safety 
10
and effectiveness of a COVID–19 vaccine; and 
11
‘‘(D) that identifies locations in the com-
12
munity served by the entity where COVID–19 
13
vaccines are administered; 
14
‘‘(2) consult with members of such communities 
15
and populations to develop the informational mate-
16
rial under paragraph (1); and 
17
‘‘(3) disseminate informational material on 
18
treatments available for covered conditions, includ-
19
ing, if applicable, treatments provided by the entity. 
20
‘‘(d) PRIORITY.—In awarding grants under this sec-
21
tion, the Secretary shall give priority to— 
22
‘‘(1) federally qualified health centers (as de-
23
fined in section 330A); 
24
‘‘(2) community-based organizations; and 
25
17:53 Jan 29, 2021
H173
8 
•HR 173 IH
‘‘(3) entities that have an agreement with a fed-
1
erally qualified health center. 
2
‘‘(e) REPORTS.— 
3
‘‘(1) REPORT TO SECRETARY.—An entity that 
4
receives a grant under this section shall submit to 
5
the Secretary a report that includes— 
6
‘‘(A) a description of each activity carried 
7
out with amounts received through the grant; 
8
and 
9
‘‘(B) an evaluation of the effectiveness of 
10
each such activity. 
11
‘‘(2) REPORT TO CONGRESS.—Not later than 3 
12
years after the date of the enactment of this section, 
13
the Secretary shall submit to Congress a report on 
14
the effectiveness of the grants entered into under 
15
this section. 
16
‘‘(f) SUPPLEMENT NOT SUPPLANT.—An entity re-
17
ceiving a grant under this section shall use grant amounts 
18
to supplement, not supplant, any other Federal, State, and 
19
local funds that would otherwise be expended by such enti-
20
ty to carry out the activities described in this section. 
21
‘‘(g) DEFINITIONS.—In this section: 
22
‘‘(1) COVERED CONDITION.—The term ‘covered 
23
condition’ has the meaning given such term in sec-
24
tion 330N. 
25
17:53 Jan 29, 2021
H173
9 
•HR 173 IH
‘‘(2) COVID–19 VACCINE.—The term ‘COVID– 
1
19 vaccine’ means a vaccine that is intended to pre-
2
vent, mitigate, or treat the virus that causes 
3
COVID–19 and— 
4
‘‘(A) is licensed under section 351 of the 
5
Public Health Service Act (42 U.S.C. 262); or 
6
‘‘(B) authorized under section 564 of the 
7
Federal Food, Drug, and Cosmetic Act (21 
8
U.S.C. 360bbb–3). 
9
‘‘(h) AUTHORIZATION
OF
APPROPRIATIONS.—To 
10
carry out this section, there is authorized to be appro-
11
priated $120,000,000 for the period of fiscal years 2021 
12
through 2022, to remain available until expended.’’. 
13
Æ 
17:53 Jan 29, 2021
H173
